Johnson & Johnson $JNJ Stock Position Decreased by Cohen Klingenstein LLC

Cohen Klingenstein LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the third quarter, Holdings Channel.com reports. The firm owned 124,109 shares of the company’s stock after selling 3,885 shares during the quarter. Johnson & Johnson makes up 1.1% of Cohen Klingenstein LLC’s holdings, making the stock its 21st largest holding. Cohen Klingenstein LLC’s holdings in Johnson & Johnson were worth $32,857,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. National Pension Service lifted its position in shares of Johnson & Johnson by 1.3% in the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares in the last quarter. IFP Advisors Inc boosted its holdings in Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B grew its position in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,563 shares in the last quarter. Signal Advisors Wealth LLC grew its position in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after purchasing an additional 6,539 shares in the last quarter. Finally, Gradient Investments LLC increased its stake in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $255.54 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm’s fifty day moving average price is $265.66 and its two-hundred day moving average price is $249.61. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The firm has a market capitalization of $615.82 billion, a P/E ratio of 38.72, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the company posted $2.80 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Leerink Partners cut their price target on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a research report on Wednesday. TD Cowen raised their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. Weiss Ratings raised Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research report on Thursday. Finally, Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $274.87.

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 87,569 shares of company stock valued at $23,064,544. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson?
• Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target.
• Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying
• Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss
• Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.